[Gastrointestinal stromal tumor molecular diagnostics in relation to the prediction of a therapeutic response to targeted biological therapy]. / Molekulární diagnostika gastrointestinálních stromálních tumoru ve vztahu k predikci terapeutické odpovedi na cílenou biologickou lécbu.
Cesk Patol
; 47(4): 148-52, 2011 Oct.
Article
em Cs
| MEDLINE
| ID: mdl-22145212
ABSTRACT
Targeted therapy based on the inhibition of the receptor tyrosine kinases has improved the outcome of patients with metastatic, recurrent and/or unresectable gastrointestinal stromal tumors (GIST). Activating mutations of KITand PDGFRA genes, which code for receptor tyrosine kinases, play an important role in the malignant transformation of stromal cells in the gastrointestinal tract. The response to targeted therapy is associated with the presence and type of mutations. Molecular identification of the primary mutational status became an important tool in predicting the response to therapy (sensibility/resistance). The identification of secondary mutations occurring in patients treated with targeted therapy may explain the cause of acquired, secondary resistance of GIST. In these cases, mutational analysis represents a tool to explain failure of the therapy and provides a rationale for alternative therapeutic strategies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Proto-Oncogênicas c-kit
/
Receptor alfa de Fator de Crescimento Derivado de Plaquetas
/
Tumores do Estroma Gastrointestinal
/
Terapia de Alvo Molecular
/
Neoplasias Gastrointestinais
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
Cs
Revista:
Cesk Patol
Ano de publicação:
2011
Tipo de documento:
Article